Third Quarter 2024 Financial Results Revenue of $1,030 million , organic constant currency growth of 1% Reported Net Income of $364 million , Adjusted Net Income of $66 million Adjusted EBITDA of $163 million , or 15.8% of Revenue Reported EPS of $0.73 , Adjusted EPS of $0.
13 Net leverage ratio of 4.3x Adjusted EBITDA Pre-tax gain of $640 million from July 2024 divestiture of the aqua business Tightening full year 2024 financial guidance to reflect current assumptions: Revenue of $4,420 to $4,450 million , with organic constant currency growth of 3% Reported Net Income of $286 to $317 million ; Reported EPS of $0.58 to $0.
64 Adjusted EBITDA of $900 to $930 million ; Adjusted EPS of $0.89 to $0.95 Received U.
S. FDA approval for ZenreliaTM and Credelio QuattroTM, bringing innovation to the largest pet health markets In 2025, innovation ramp expected to accelerate organic constant currency revenue growth to mid-single digits, with adjusted EBITDA growth, excluding the aqua divestiture, expected in the low single digits, with underlying mid-single growth offset by expected headwinds from U.K.
CMO GREENFIELD, Ind. , Nov. 7, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN ) today reported financial results for the third quarter of 2024, provided guidance for the fourth quarter of 2024, and tightened guidance for the full year 2024.
"Elanco's expanding portfolio supported our fifth consecutive quarter of underlying organic constant currency revenue growth in the t.
